Information collected through HAE Canada’s surveys is used to create patient submissions. These documents provide payers with important information that will be used to help determine access to new treatments.
2022
Patient Input for CADTH Reimbursement Review for Berotralstat (Orladeyo) & CADTH Reimbursement Review Feedback on Draft Recommendations *
* CADTH’s first response was to not recommend reimbursement for Orladeyo. HAEC was then given the opportunity to submit feedback on this initial decision. This feedback, along with feedback from other stakeholders, helped CADTH decide to reverse their decision and CADTH now recommends reimbursement for Orladeyo.
2019
Patient Input for Lanadelumab (TAKHZYRO): Drug Evaluation Questionnaire for Patient and Caregiver Associations and Groups
Patient Input for HAEGARDA (C1 Esterase Inhibitor Subcutaneous – Human)
Patient Input Lanadelumab (TAKHZYRO): CDR and pCODR Programs
2014
Patient Input for Icatibant (Firazyr): Common Drug Review
